Loading clinical trials...
Loading clinical trials...
Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide Treatment and Using a Population of Patients With Multiple Sclerosis as a Reference
Conditions
Interventions
teriflunomide
Interferon-β-1
+1 more
Locations
14
Austria
Investigational Site Number 040001
Vienna, Austria
Investigational Site Number 124005
Calgary, Canada
Investigational Site Number 124003
Greenfield Park, Canada
Investigational Site Number 124002
London, Canada
Investigational Site Number 124007
Montreal, Canada
Investigational Site Number 124008
Ottawa, Canada
Start Date
September 1, 2011
Primary Completion Date
January 1, 2012
Completion Date
January 1, 2012
Last Updated
February 18, 2016
NCT07225504
NCT06276634
NCT06809192
NCT05359653
NCT07426991
NCT07376772
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions